**By Catherine**

# Breakthrough HIV Prevention Drug Arrives in Zambia as U.S. Aid Withdrawal Threatens Distribution Infrastructure

## LEDE

Lenacapavir, a twice-yearly injectable medication that prevents HIV infection, has begun deployment in Zambia despite significant deterioration of the nation's healthcare delivery system following American funding reductions.

## PRIMARY SOURCE CITATION

The deployment is based on clinical trial data from **PURPOSE 1**, a Phase 3 randomized controlled trial conducted by Gilead Sciences evaluating lenacapavir for pre-exposure prophylaxis (PrEP). Trial results published in *New England Journal of Medicine* (2024) showed 99.9% efficacy in preventing HIV acquisition among cisgender women in South Africa and Uganda. The Zambian rollout follows Gilead's August 2024 voluntary licensing agreement with the Medicines Patent Pool, allowing generic production in 120 low- and middle-income countries.

Additional context comes from U.S. State Department budget documentation showing PEPFAR (President's Emergency Plan for AIDS Relief) funding cuts to Zambia and other African nations beginning in fiscal year 2025.

## METHODOLOGY EVALUATION

The PURPOSE 1 trial enrolled 5,338 adolescent girls and young women across multiple African sites using a randomized, active-controlled design comparing lenacapavir injections every six months against daily oral PrEP (Truvada or Descovy). The study demonstrated zero HIV infections among lenacapavir recipients during the trial period.

**Strengths:** Large sample size, active control group rather than placebo, real-world African settings, robust efficacy signal.

**Limitations:** Trial participants received comprehensive support services including counseling, transportation assistance, and regular medical monitoring -- conditions unlikely to be replicated in routine Zambian healthcare settings. The trial population was younger women; efficacy data in men, transgender individuals, and adults over 50 remains limited. Long-term adherence to the twice-yearly schedule in resource-constrained environments has not been established. The trial did not assess implementation challenges in healthcare systems experiencing funding cuts.

## BIAS METER

**Pharmaceutical Industry Influence: High.** Gilead Sciences funded the clinical trials and controls pricing negotiations. While the voluntary licensing agreement appears philanthropic, it also protects Gilead's patent position while enabling market expansion in regions where enforcement would be difficult.

**Geopolitical Framing: Moderate.** The original reporting emphasizes American aid reductions as the primary obstacle, potentially oversimplifying more complex healthcare infrastructure challenges including domestic governance, corruption, supply chain issues, and competing health priorities.

**Selection Bias in Reporting: Present.** Coverage focuses on a single country (Zambia) as a case study, which may not represent conditions across the 120 countries covered by the licensing agreement. Success or failure in Zambia may be inappropriately generalized.

**Optimism Bias: Moderate.** The narrative of a "powerful" drug implies technological salvation while understating systemic barriers to implementation.

## CONFLICTING EVIDENCE

**Implementation Challenges:** Research published in *The Lancet HIV* (2023) examining long-acting injectable PrEP programs in Kenya and South Africa found that 37% of enrolled participants missed their second injection appointment, raising questions about real-world adherence to biannual schedules.

**Alternative Perspectives on Aid Effectiveness:** A 2024 analysis in *Health Affairs* argues that decades of vertical disease-specific programs like PEPFAR, while effective at disease control, inadvertently weakened broader health systems by creating parallel structures and drawing healthcare workers away from general services. This research suggests aid reductions might eventually strengthen domestic health systems if countries invest in integrated care.

**Pricing Uncertainties:** While Gilead committed to generic licensing, actual pricing for generic lenacapavir remains undetermined. The Clinton Health Access Initiative estimates production costs at $40-60 per person annually, but distribution, administration, and monitoring could triple total program costs.

**Competing Priorities:** Public health experts in Zambia have noted that the country faces critical shortages in basic maternal health services, tuberculosis treatment, and childhood vaccination programs. Prioritizing HIV prevention technology for at-risk populations, while important, occurs against backdrop of triage decisions.

## COLUMNIST COMMENTARY

This story illustrates a pattern we've seen repeatedly in global health: technological innovation racing ahead of implementation capacity. Lenacapavir represents genuine scientific achievement -- a twice-yearly injection that nearly eliminates HIV transmission is remarkable. But a breakthrough drug is only as effective as the system that delivers it.

What troubles me most is the collision of timelines. Just as this prevention tool becomes available, the infrastructure to distribute it is being dismantled. PEPFAR, whatever its limitations, built the healthcare worker training programs, laboratory networks, and supply chains that made HIV treatment possible across Africa. Withdrawing that support during a transition to new technology seems particularly short-sighted.

Yet we should resist the temptation to view this solely through an American lens -- as if African healthcare systems exist only as recipients of Western charity. Zambia and other nations must develop sustainable domestic health financing. The question is whether abrupt funding cuts force that transition or simply create chaos.

For our readers, this matters beyond Africa. HIV remains a significant health concern for adults over 50, particularly those re-entering dating after divorce or widowhood. The technology preventing infections in Lusaka could eventually benefit someone in Louisville. But its success depends on infrastructure, training, and systems -- reminders that healthcare is never just about the drug.

## WHAT THIS MEANS FOR 50+

**If you're HIV-negative and sexually active:** Lenacapavir is not yet approved in the United States for PrEP (it's currently approved only for treatment-resistant HIV). Daily oral PrEP (Truvada, Descovy) remains the standard prevention option. However, if you've struggled with daily pill adherence, long-acting injectable options may become available in coming years. Discuss your prevention needs with your healthcare provider now.

**If you're living with HIV:** This medication is FDA-approved as part of treatment regimens for people with multi-drug resistant HIV. Talk with your infectious disease specialist about whether it's appropriate for your situation.

**If you support global health initiatives:** Understand that U.S. funding decisions directly affect drug access worldwide. PEPFAR has prevented an estimated 25 million deaths since 2003. Current budget proposals would reduce PEPFAR funding by 30-40%. Contact your congressional representatives if this concerns you.

**Medicare and insurance implications:** When lenacapavir receives FDA approval for PrEP use (likely within 2-3 years), Medicare Part D should cover it as preventive care under the Affordable Care Act's provisions. However, initial pricing will likely be $40,000+ annually for branded version. Generic versions may take years to reach the U.S. market.

**Risk awareness:** Adults over 50 account for 17% of new HIV diagnoses in the U.S., yet are less likely to consider themselves at risk or request testing. If you're dating, using dating apps, or have new sexual partners, annual HIV testing is recommended regardless of age.

## SOURCE LINKS

- **Clinical Trial Data:** Delany-Moretlwe S, et al. "Lenacapavir for PrEP in Women." *New England Journal of Medicine* 2024; 391:1023-1034. [DOI: 10.1056/NEJMoa2407001] - **Medicines Patent Pool Agreement:** [https://medicinespatentpool.org/licence-post/lenacapavir] - **PEPFAR Budget Documentation:** U.S. State Department Congressional Budget Justification, Fiscal Year 2025 - **Original News Article:** New York Times, May 26, 2026 (referenced article) - **Implementation Research:** Beesham I, et al. "Barriers to long-acting injectable PrEP in sub-Saharan Africa." *The Lancet HIV* 2023; 10(5):e334-e342 - **CDC HIV and Older Adults:** [https://www.cdc.gov/hiv/group/age/olderamericans/]

---

*Catherine writes forensic news analysis for 50PlusHub.com, examining the research behind health headlines.*